Matteo Di Bari

Dr. Matteo Di Bari

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
JMJoannna Mikulak
Joannna Mikulak
FOFerdinando Oriolo
Ferdinando Oriolo
EBElena Bruni
Elena Bruni
ARAlessandra Roberto
Alessandra Roberto
Federico Simone ColomboFederico Simone Colombo
Federico Simone Colombo
DMDomenico Mavilio
Domenico Mavilio
γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent antitumor activities. However, little is known about their origin, phenotype, and clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut specificity, homing, and functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, and intestine, either disease-free, affected by CRC, or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a subset of cytotoxic Vδ1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46 + /Vδ1 IELs depends both on distinctive features of Vδ1 thymic precursors and gut-environmental factors. Either the constitutive presence of NKp46 on tissue-resident Vδ1 intestinal IELs or its induced expression on IL-2/IL-15–activated Vδ1 thymocytes are associated with antitumor functions. Higher frequencies of NKp46 + /Vδ1 IELs in tumor-free specimens from CRC patients correlate with a lower risk of developing metastatic III/IV disease stages. Additionally, our in vitro settings reproducing CRC tumor microenvironment inhibited the expansion of NKp46 + /Vδ1 cells from activated thymic precursors. These results parallel the very low frequencies of NKp46 + /Vδ1 IELs able to infiltrate CRC, thus providing insights to either follow-up cancer progression or to develop adoptive cellular therapies.

1 August 2020 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
GMGiuseppe Mercante
Giuseppe Mercante
FFFabio Ferreli
Fabio Ferreli
AVArmando De Virgilio
Armando De Virgilio
FGFrancesca Gaino
Francesca Gaino
Matteo Di BariMatteo Di Bari
Matteo Di Bari
GSGiuseppe Spriano
Giuseppe Spriano
In December 2019, an outbreak of pneumonia of unknown origin was observed in the city of Wuhan, Hubei Province, China. A novel coronavirus, the 2019 new coronavirus, then named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the etiologic agent responsible for the outbreak.1,2 Coronavirus disease 2019 (COVID-19) then spread outside Hubei to many countries outside China. It was defined as a pandemic by the World Health Organization on March 11, 2020.3

1 February 2020 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
Domenico TestaDomenico Testa
Domenico Testa
Matteo Di BariMatteo Di Bari
Matteo Di Bari
MNMichele Nunziata
Michele Nunziata
GCGeneroso De. Cristofaro
Generoso De. Cristofaro
GMGiuseppe Massaro
Giuseppe Massaro
GMGaetano Motta
Gaetano Motta

2 January 2021 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
GCGiovanni Colombo
Giovanni Colombo
FFFabio Ferreli
Fabio Ferreli
Matteo Di BariMatteo Di Bari
Matteo Di Bari
GCGiovanni Cugini
Giovanni Cugini
SMStefano Miceli
Stefano Miceli
APArturo Poletti
Arturo Poletti

30 October 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AVArmando De Virgilio
Armando De Virgilio
GMGiuseppe Mercante
Giuseppe Mercante
FGFrancesca Gaino
Francesca Gaino
PYPhil Yiu
Phil Yiu
TMTiziana Mondello
Tiziana Mondello
GSGiuseppe Spriano
Giuseppe Spriano

18 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AVArmando De Virgilio
Armando De Virgilio
Oreste IoccaOreste Iocca
Oreste Iocca
Luca MalvezziLuca Malvezzi
Luca Malvezzi
PMPasquale Di Maio
Pasquale Di Maio
RPRaul Pellini
Raul Pellini
GSGiuseppe Spriano
Giuseppe Spriano
The aim of this systematic review with meta-analysis was to investigate the available literature on transoral approaches in the treatment of hypopharyngeal squamous cell carcinoma, with a special focus on transoral robotic surgery (TORS). A systematic review was conducted according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) check-list, and 15 studies were included. Five of the included studies evaluated TORS, while ten studies focused on transoral laser microsurgery (TLM) for the treatment of early or advanced stage hypopharyngeal cancer. Overall, survival rates of TLM and TORS studies, analyzed together in the cumulative meta-analysis, were 66.4% (95% confidence interval (CI) 54.3%–76.7%) at 36+ months of follow up. The TORS subgroup showed a higher cumulative survival rate (85.5%, 95% CI 55.8%–96.5%) compared to TLM (58.5%, 95% CI 46.6%–69.6%). Cumulative data showed that 29.3% (95% CI 24.0%–35.3%) of deaths were attributable to cancer. The results were similar between TLM and TORS studies. The larynx function preservation cumulative rate was 94.3% (95% CI 91.8%–96.1%). The results were similar among the two subgroups. The present review supports the use of transoral approaches in the treatment of hypopharyngeal cancer. TORS is oncologically sound and provides excellent functional results with low complication rates.